pI: 7.683 |
Length (AA): 481 |
MW (Da): 54492 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
5 | 427 | 2acx (A) | 44 | 470 | 23.00 | 0 | 1 | 1.06 | 0.18 |
130 | 415 | 1mq4 (A) | 127 | 388 | 32.00 | 0 | 1 | 1.01 | -1.03 |
16 | 70 | 1dvp (A) | 153 | 213 | 40.00 | 0.42 | 0.37 | 0.351045 | 0.83 |
19 | 471 | 3nyn (A) | 54 | 514 | 23.00 | 0 | 1 | 1.05019 | 0.84 |
134 | 417 | 3hzt (A) | 74 | 344 | 29.00 | 0 | 1 | 0.866837 | -0.24 |
206 | 407 | 2jii (A) | 250 | 452 | 18.00 | 0.000085 | 0.72 | 0.556358 | 0.18 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | metacyclic. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | amastigotes. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_146003)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.26.2450 | protein kinase, putative |
Leishmania donovani | LdBPK_262540.1 | protein kinase, putative |
Leishmania infantum | LinJ.26.2540 | protein kinase, putative |
Leishmania major | LmjF.26.2510 | protein kinase, putative |
Leishmania mexicana | LmxM.26.2510 | protein kinase, putative |
Trypanosoma brucei gambiense | Tbg972.9.290 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.9.1570 | calcium/calmodulin-dependent protein kinase, putative |
Trypanosoma congolense | TcIL3000_9_190 | protein kinase, putative |
Trypanosoma congolense | TcIL3000_9_160 | protein kinase, putative |
Trypanosoma cruzi | TcCLB.503925.30 | calcium/calmodulin-dependent protein kinase, putative |
Trypanosoma cruzi | TcCLB.510347.60 | calcium/calmodulin-dependent protein kinase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.160.0500 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.0500 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.0500 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.160.0500 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.5
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 20.8% | 313 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 25.1% | 295 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 20.7% | 309 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 25.9% | 313 aa | Compounds | References |
Xenopus laevis | Aurora kinase B-A | 361 aa | 25.1% | 315 aa | Compounds | References |
Rattus norvegicus | c-Jun N-terminal kinase 3 | 464 aa | 23.8% | 386 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 19.9% | 292 aa | Compounds | References |
22 literature references were collected for this gene.